Drug intelligence / Profile preview

DWC202010

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202010 is an **appetite suppressant small molecule** developed as part of anti-obesity therapies. It is being studied both as a single agent and in combination with enavogliflozin (an SGLT2 inhibitor) for obesity and other metabolic conditions. Its exact molecular target and chemical structure have not been publicly disclosed in available sources. DWC202010 is a new molecular entity and forms part of the combination drug DWP 306001, which combines enavogliflozin and DWC202010 for enhanced efficacy in obesity management[2][3].

Beyond the preview

Go deeper on DWC202010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202010.

Explore the full profile